从连续性进行统计， 有2只股获南向资金连续3天以上净买入，连续净买入天数较多的有建设银行、美 团-W，连续净买入天数分别为7天、4天。以其间净买入金额统计，净买入金额最多的是建设银行，合 计净买入为55.09亿港元，其次是美团-W合计净买入为24.40亿港元。有2只股获连续净卖出，净卖出金 额居前的有腾讯控股、小米集团-W等，合计净卖出金额分别为152.32亿港元、17.32亿港元。（数据 宝） | 代码 | 简称 | 成交金额（万港元） | 成交净买入（万港元） | 今日涨跌幅（%） | | --- | --- | --- | --- | --- | | 00939 | 建设银行 | 191005.37 | 68932.56 | 0.58 | | 03690 | 美团-W | 234601.69 | 65596.17 | 0.66 | | 00883 | 中国海洋石油 | 197099.26 | 58698.23 | 1.48 | | 01093 | 石药集团 | 74160.80 | 36372.53 | 3.49 | | 01530 | 三生制药 | 228598.21 | 26829.29 | 8.7 ...

Group 1 - The core viewpoint of the article highlights the performance of the China Securities Hong Kong Stock Connect TMT Index, which has seen a 10.93% increase over the past month and a 22.64% increase year-to-date [1] - The index consists of 50 listed companies in the TMT sector selected from the Hong Kong Stock Connect, reflecting the overall performance of related industry companies [1] - The top ten weighted companies in the index include Xiaomi Group-W (21.12%), Tencent Holdings (14.91%), and China Mobile (14.28%) [1] Group 2 - The index is adjusted semi-annually, with changes implemented on the next trading day following the second Friday of June and December [2] - In special circumstances, the index may undergo temporary adjustments, such as removing companies that are delisted or adding new TMT companies that rank in the top ten by market capitalization [2] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with 52.50% in communication services and 47.50% in information technology [1]

Group 1 - The core index of the CSI Hong Kong Stock Connect Medical Theme Index has shown a recent increase of 9.41% over the past month, while it has decreased by 0.61% over the last three months and increased by 18.99% year-to-date [1] - The index consists of 50 listed companies involved in medical devices, medical business and services, pharmaceuticals, and biotechnology services, reflecting the overall performance of the medical sector within the Hong Kong Stock Connect [1] - The top ten weighted companies in the index include WuXi Biologics (16.6%), JD Health (11.41%), Alibaba Health (7.52%), Sinopharm (5.68%), WuXi AppTec (5.51%), Weigao Group (3.66%), Genscript Biotech (3.55%), Innovent Biologics (2.4%), CanSino Biologics (2.23%), and MicroPort Scientific (2.2%) [1] Group 2 - The industry composition of the index shows that medical business and services account for 35.62%, pharmaceutical and biotechnology services for 31.58%, medical devices for 11.75%, chemical drugs for 10.53%, biological drugs for 10.09%, and traditional Chinese medicine for 0.42% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or spin-offs [2]

金融界5月20日消息，上证指数上涨0.38%，中证港股通成长策略指数 (港股通成长策略，932152)报 1253.67点。 数据统计显示，中证港股通成长策略指数近一个月上涨10.06%，近三个月上涨0.64%，年至今上涨 20.87%。 从中证港股通成长策略指数持仓样本的行业来看，可选消费占比40.48%、信息技术占比15.30%、通信 服务占比13.25%、医药卫生占比8.18%、金融占比7.28%、工业占比3.42%、原材料占比2.94%、主要消 费占比2.92%、能源占比2.45%、公用事业占比2.12%、房地产占比1.65%。 资料显示，指数样本每季度调整一次，样本调整实施时间分别为每年3月、6月、9月和12月的第二个星 期五的下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在 下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将 其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。当港 股通证券范围发生变动导致样本不再满足互联互通资格时，指数将相应调整。 本文源自：金融界 作者：行情君 据了解 ...

港股通互联网ETF(159792)成交额超20亿元，当前涨幅为1.3%，溢价率为-0.63%，成交额20.02亿元，近 1月份额减少5.25亿份，该基金支持T+0交易。 ...

宜明昂科-B(01541)涨超10%，与Axion Bio合作近期再获500万美元付款，IMM0306自免领域前景广阔。 基石药业-B(02616)涨超18%，近期在2025 AACR大会发布五项最新研究成果。 荣昌生物(09995)再涨超14%，维迪西妥单抗新增适应症，一季度业绩略超预期。 顺丰同城(09699)再涨超5%，即时消费市场竞争加剧，第三方即时配送平台有望显著受益。 智通财经APP获悉，港股恒生指数涨1.29%，涨301点，报23634点；恒生科技指数涨1.32%；恒生生物科 技指数大涨4.26%。港股早盘成交1211亿港元。 宁德时代(03750)港交所挂牌首日，上午大涨超16%。 三生制药(01530)暴涨35%逼近历史前高，公司与辉瑞就PD-1/VEGF双抗达成授权协议。辉瑞将支付12.5 亿美元不可退还且不可抵扣的首付款，最高可达48亿美元的开发、监管批准和销售里程碑付款，以及根 据授权地区产品销售额计算得到的两位数百分比的梯度销售分成。 先声药业(02096)再涨5.4%，先诺欣5月以来销量大幅增长，后续多款新药获批在望。 布鲁可(00325)涨超2%创上市新高，公司有望6月进入港股通 ...

Market Overview - The Hang Seng Index rose 2.1% last week, closing at 23,345 points, marking the fifth consecutive week of gains[1] - The Hang Seng Tech Index increased by 2.0%, closing at 5,281 points[1] - Average daily trading volume increased by 16.1% week-on-week to over HKD 232.5 billion[1] - Net outflow from the Hong Kong Stock Connect was approximately HKD 8.7 billion for the week, with a significant reduction in cumulative net inflow to HKD 16.8 billion over the past 20 days[1] Sector Performance - The financial sector surged by 3.8%, driven mainly by domestic banks and insurers[1] - Industrial, energy, and telecommunications sectors also saw gains of 2% or more over the week[1] Investment Sentiment - Since mid-April, the flow of funds through the Hong Kong Stock Connect has been volatile, with a record net outflow of HKD 18.5 billion on May 12, indicating a cautious stance from southbound investors[2] - The current AH premium index has dropped to the 16.0 percentile since 2020, suggesting insufficient value for aggressive buying[2] - The Hang Seng Index faces significant resistance in the 23,500-24,000 point range, with potential for continued volatility if southbound fund support diminishes[2] Macro Dynamics - Moody's downgraded the U.S. long-term sovereign credit rating from Aaa to Aa1, citing structural debt imbalance and increasing fiscal deficit pressures[3] - The U.S. federal debt-to-GDP ratio is projected to rise from 98% in 2024 to 134% by 2035, raising concerns about long-term repayment capacity[3] - Despite the downgrade, Moody's maintains that systemic risk has not reached a critical point, and market reactions will depend more on policy responses and economic data than on the rating change itself[3] Industry Developments - The Hang Seng Healthcare Index rose by 0.6%, with notable gains from companies like CSPC Pharmaceutical (3.1% to 3.9% increase)[4] - CSPC signed an exclusive licensing agreement for a cancer treatment in the U.S., receiving an upfront payment of USD 15 million and potential milestone payments of up to USD 25 million[4] - The IPO of Heng Rui Medicine received a "subscribe" rating, with projected revenue growth of 7.3% and net profit growth of 10.1% for 2023-24[4][7] New Drug Approvals - Rongchang Biotech's new indication for its drug has been approved, expected to boost sales significantly[11] - The company reported a 59.1% year-on-year increase in revenue to RMB 530 million for Q1 2025, with a reduction in net loss by 27.2%[13] - Target price for Rongchang Biotech has been raised to HKD 45.00, reflecting positive adjustments in revenue and profit forecasts[14]

Group 1 - CICC expects companies like Mixue Group (02097) and Bruker (00325) to be included in the Hong Kong Stock Connect list following the recent adjustments to the Hang Seng Index [1] - Horizon Robotics, listed in October last year, has met the requirements for inclusion in the Hong Kong Stock Connect after being added to the Hang Seng Index in February [1] - CICC estimates that passive fund inflows for companies like ZTO Express and NetEase will be significant, with expected inflows of $128 million and $218 million respectively [1] Group 2 - The Nasdaq Golden Dragon China Index fell by 0.17%, while major US indices showed slight gains, with the Dow Jones up 0.32% [2] - Notable gains were seen in the pharmaceutical and precious metals sectors, with Novavax rising over 15% [2] - The Hang Seng Index ADR increased by 0.52%, indicating a positive sentiment in the Hong Kong market [2] Group 3 - The World Health Organization's Director-General emphasized the need for global cooperation to address unprecedented public health challenges during the 78th World Health Assembly [3] - The WHO faces a budget shortfall of $1.7 billion over the next two years, which poses a significant challenge to its global health mission [3] Group 4 - Huawei's HarmonyOS-powered personal computers were officially launched, marking a significant breakthrough for domestic operating systems in the PC sector [4] - The HarmonyOS computers support over 1,100 external device connections and have adapted over 1,000 applications [4] Group 5 - Shandong Xinhua Pharmaceutical received approval for the listing of Eicosapentaenoic Acid Ethyl Ester, marking a significant milestone in its product development [5] - The approval was granted by the National Medical Products Administration after the company submitted its application in June 2023 [5] Group 6 - Huaxing Capital announced the successful listing of its portfolio company, Weigao Blood Purification Products, on the Shanghai Stock Exchange [6] - Tian Cai Holdings is negotiating to provide instant delivery systems for major online supermarkets, enhancing its service offerings [6] Group 7 - BYD established its European headquarters in Hungary, reinforcing its commitment to long-term development in Europe [7] - The establishment of the headquarters signifies deep integration with the local automotive industry [7] Group 8 - New China Life Insurance was approved to participate in the third batch of long-term investment reform trials, aiming to enhance capital market development [8] - The company plans to establish the third phase of the Honghu Fund to facilitate long-term investments [8] Group 9 - Jianbei Miao Miao expects a significant increase of at least 50% in its annual net profit attributable to shareholders for the fiscal year ending March 31, 2025 [9] Group 10 - Leap Motor reported a revenue of 10.02 billion yuan for Q1 2025, representing a year-on-year growth of 187.1% [10] - The growth was driven by a 162.1% increase in sales volume and a 4.9% increase in revenue per vehicle [10] Group 11 - Alibaba Health reported a 13.2% increase in revenue to 30.598 billion yuan for the fiscal year ending March 31, 2025, with adjusted net profit rising by 35.6% [11] - The company achieved a profit attributable to shareholders of 1.432 billion yuan, marking a 62.14% increase [11] Group 12 - Alibaba Pictures reported a 33% increase in revenue to 6.702 billion yuan for the fiscal year ending March 31, 2025, with a net profit attributable to shareholders of 364 million yuan [12] Group 13 - Trip.com Group reported a net operating revenue of 13.8 billion yuan for Q1 2025, reflecting a 16% year-on-year increase [13] - The net profit attributable to shareholders remained stable at 4.3 billion yuan compared to the previous year [13] Group 14 - CSPC Pharmaceutical received FDA fast track designation for its CPO301 drug, aimed at treating advanced non-small cell lung cancer [14] - The drug has also been approved for clinical trials in China [14]

（来源：金石杂谈） 转自：金石杂谈 5月19日，长城基金公募研总廖瀚博火了，一起看看他的投资成绩单。 长城基金廖瀚博，硕士研究生，2012年7月至2014年6月曾就职于长城证券，20114年7月至2015年10月曾就职于海通证券，2015年10月至2017年6月曾就职 于深圳鼎诺投资，这家因经营异常在2023年年初被协会注销。 2017年6月，他正式进军公募，成为长城基金一位研究员，此后做了基金经理助理，到了2018年3月正式成为基金经理。目前他的投资经验已有7年，也成 功升职为公司研究部总经理。 截至目前，廖总管理5只基金，但业绩确实喜忧参半，更确切的说业绩并不好，两款业绩最优异的产品，一只盈利90%，一只盈利75%，但均是2018年和 2019年的产品，而且盈利90%这只你看它的C产品成立三年亏了36%；而近4年来看，他除了2023年12月接管的一只基金盈利近15%，其他三款产品全部录 得约30%的任职亏损。 | 100 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 基金代码 | 基金名称 | 相关链接 | 基金类型 ...

港股不设涨跌停限制，个股单日暴跌90%以上、甚至归零的案例并不罕见。从港股市场筛选相对稳 健的标的纳入港股通，供A股投资者选择，可以在一定程度上过滤市场风险，降低单日极端暴跌的概 率，从而维护港股通投资者的信心。 近日，深交所某上市公司A股复牌并撤销其他风险警示，同时被调入深港通下的港股通标的证券名 单。这一调整导致该上市公司H股股价暴涨，在股价冲顶阶段，二股东通过集中竞价方式累计大量减持 H股，随后股价自高点暴跌超六成。笔者认为，应改革港股通标的筛选机制。 但从目前港股通市场的实际运行情况来看，其中的风险仍不容忽视。本案上市公司因重新纳入港股 通，成为其H股遭爆炒的导火索，股价短期内大幅上涨，大股东趁机高位减持——这一在A股市场常见 的情形，如今在H股市场再度上演。此外，此前一些具有庄股特征的个股因被纳入恒生综合指数成分 股，进而成为港股通标的后，也曾出现单日股价巨幅暴跌的情况。 该上市公司A股虽撤销其他风险警示，但基本面并不乐观：2021年至2023年连续亏损，2024年度每 股收益-0.05元，今年一季度每股收益0.0068元、同比下降97.5%。其H股被重新纳入港股通标的，源于 《深交所深港通业务实施 ...